R

Roche

Global pharmaceuticals and diagnostics company

Head of MSAT Technology Transfer

Full-TimeUpdated on 10/15/2026
No salary listed
Expert
Bachelor's
Shanghai, China
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A bachelor's degree or above is required; a degree in Pharmaceutical or Biological fields is preferred.
  • More than 10 years of MSAT experience in the injection pharmaceutical industry is required; multinational biopharma experience is preferred.
  • At least 5 years of hands-on technology transfer experience is required.
  • At least 5 years of people management experience, with a proven record of leading and developing teams, is required.
  • Extensive experience in strategic aseptic filling facility projects, including design, commissioning, and qualification, is required.
  • Expertise in new-facility startup readiness, including organization, people, and operational management systems, is required.
  • Strong knowledge of cGMP and pharmaceutical regulations, especially in the biological industry, is required.
  • Strategic thinking and the ability to translate high-level strategies into actionable plans are required.
  • Proficiency in leveraging agile methodologies to drive efficiency and adaptability is required.
  • Fluent English communication skills are required.
Responsibilities
  • Lead technology transfer, PPM introduction, and compliance activities to ensure manufacturing readiness.
  • Drive strategic project realization, including qualification, manufacturing readiness, and startup.
  • Oversee technology-transfer operations, including process design and troubleshooting, adherence to cGMP, and compliance with Roche quality policies and international regulatory requirements.
  • Identify, evaluate, and implement technologies and methodologies to improve process control, automation capabilities, and product quality consistency.
  • Enable and empower the team through VACC leadership behaviors and strategic project development in China.
  • Serve as the key interface with manufacturing, quality assurance, and engineering to align processes, prepare for production, and drive cross-functional collaboration.
  • Coordinate with global team members, internal stakeholders, and external partners to execute internal and external technology transfers; provide updates, share knowledge, and coordinate initiatives and milestones.
  • Develop and execute strategies, remove barriers, advance people and technical capabilities, and support individuals in performing effectively.
  • Lead and develop the team, foster individual growth and collective skills, and build team cohesion.
  • Build and sustain strategic alliances with site leaders to align priorities and coordinate cross-functional operations.
  • Oversee and continuously improve site safety, health, and environmental procedures and programs; drive site safety performance and a proactive safety culture.
  • Direct and develop the organization and its team members to achieve organizational and professional objectives.
  • Build a talent pipeline and succession plans for key positions.
  • Drive continuous improvement and operational excellence using lean leadership principles.
  • Promote an innovation-driven, high-performance culture based on empowerment and ownership.
  • Contribute to the design and construction of the new facility, including IOPQ, APS, and process validation for technology transfer.
  • Lead and develop the process engineering team, supporting innovation, technical rigor, and cross-functional collaboration.
  • Act as a technical subject matter expert and people leader, guiding team members in technology transfer, manufacturing support, and troubleshooting.
  • Align process engineering strategies with site and global technical roadmaps in collaboration with MSAT leadership.
  • Lead implementation of upstream and downstream processes, including scale-up and validation, in compliance with FDA, EMA, and cGMP standards.
  • Provide technical support during transfer and startup; troubleshoot scale-up, process validation, and initial production campaign issues; monitor process performance and implement corrective measures.
  • Collaborate cross-functionally to improve transferred processes for scalability, robustness, and regulatory compliance.
  • Partner with global teams to integrate technology into GMP manufacturing and support scale-up and execution.
  • Participate in global technology forums and steering committees and contribute to innovation pipelines.
  • Apply insights from international collaboration to introduce process-intensification methods, including novel bioreactor design, high-efficiency downstream processing systems, and process digitalization.
  • Respond to agency inquiries, represent the facility during regulatory inspections and audits, and participate in regulator and global quality audit responses.
  • Lead global cross-functional projects among research and development, engineering, quality, and site operations teams, integrating global requirements into local operations and ensuring shared accountability.
Desired Qualifications
  • Multinational biopharma experience is preferred.
  • A degree in Pharmaceutical or Biological fields is preferred.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.